RK

Raghul Komalam Sadasivan

Active Director Director DIN 09835824
DIN 09835824 First appointment Jan 2023 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2023
Shareholding value β€’β€’β€’β€’ Premium profile

About Raghul Komalam Sadasivan

Data last updated:

Raghul Komalam Sadasivan is a Director at Hrbs Tesera Pharma Private Limited (since 2023). The company operates in Chemicals.

DIN 09835824
Primary Designation Director
Industry Chemicals
First Appointment 17 Jan 2023
Oldest Company Age 3 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Hrbs Tesera Pharma Private Limited U24290KL2023PTC080025
Director17 Jan 20232023Active

Directorship timeline

Open interactive timeline →
Hrbs Tesera Pharma Private Limited
Premium access

Shareholding and investment profile for Raghul Komalam Sadasivan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Raghul Komalam Sadasivan

Raghul Komalam Sadasivan currently holds 1 directorship: Hrbs Tesera Pharma Private Limited (Director, since 17 Jan 2023).

Raghul Komalam Sadasivan was first appointed on 17 Jan 2023 as Director at Hrbs Tesera Pharma Private Limited.

The current boards of Raghul Komalam Sadasivan's companies include Bibin Balachandran (Hrbs Tesera Pharma Private Limited), Jaganathan Nair Nalinakumari Harikrishnan (Hrbs Tesera Pharma Private Limited), Sarath Kumar Sasidharan Pillai (Hrbs Tesera Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available